<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05041582</url>
  </required_header>
  <id_info>
    <org_study_id>Co-STARS</org_study_id>
    <nct_id>NCT05041582</nct_id>
  </id_info>
  <brief_title>SSRIs and TDCS Enhance Post-stroke Motor Recovery</brief_title>
  <official_title>Combining SSRIs and TDCS to Enhance Motor Recovery After Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chih-Wei Tang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Far Eastern Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-stroke motor recovery is compelling but limited. Current rehabilitation has less impacts&#xD;
      on the plateau that spontaneous biological recovery could be expected. The advances in&#xD;
      non-invasive neuromodulation and neurophysiological characterization of critical motor&#xD;
      recovery period enable breaking the proportional recovery limitation. Our pilot studies&#xD;
      demonstrated the safety and responsiveness of combing dual transcranial direct current&#xD;
      stimulation (tDCS) and motor training in subacute stroke patients. There is also strong&#xD;
      evidence that selective serotonin reuptake inhibitors (SSRIs) can substantially increase the&#xD;
      effects of tDCS and improve motor function after stroke, even in the absence of depression.&#xD;
      This proposal aims to prove the potential of combining of tDCS and the commonly used SSRI&#xD;
      citalopram to improve response to a daily motor training intervention in acute stroke&#xD;
      patients (Co-STARS trial).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, sham-controlled study in 80 patients with first-ever,&#xD;
      unilateral, subcortical ischemic stroke 0.5-4 weeks after stroke onset with moderate to&#xD;
      severe hemiparesis. Participants were randomized into four groups underwent either real dual&#xD;
      tDCS [ipsilesional primary motor cortex (M1) anodal stimulation and contralesional M1&#xD;
      cathodal stimulation; 2 mA for 20 mins; 10 sessions within 2 weeks] with citalopram or&#xD;
      placebo, or sham stimulation with citalopram or placebo. All will receive concurrent&#xD;
      hospitalized intensive rehabilitation of 2 daily sessions of 90-minute physiotherapy. Action&#xD;
      reach am test (ARAT), Fugl-Meyer Assessment (FMA), multimodality MRI and EEG will be measured&#xD;
      at baseline and after 2 weeks' tDCS modulation. The primary outcome is the ARAT at 3 months&#xD;
      after intervention. The combination of tDCS and a SSRI will be expected to improve response&#xD;
      to motor training more effectively than either intervention alone. The enhanced&#xD;
      responsiveness will be correlated or predicted by biomarkers from multimodality MRI or EEG.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Motor scores 3 months after intervention</measure>
    <time_frame>3 months after intervention</time_frame>
    <description>Motor scores include Action research arm test (0-66, higher scores mean a better outcome) and Fugl-Meyer Assessment (0-54, higher scores mean a better outcome)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Stroke</condition>
  <condition>Motor</condition>
  <arm_group>
    <arm_group_label>Real tDCS + Citalopram + Rehabilitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Real tDCS, 2 mA for 20 mins per session, 10 sessions within 2 weeks&#xD;
Citalopram 10mg oral intake daily for 3 months, since 2 weeks before tDCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tDCS + Citalopram + Rehabilitation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham tDCS, ramped up over 10 seconds and then reduced to 0mA, 10 sessions within 2 weeks&#xD;
Citalopram 10mg oral intake daily for 3 months, since 2 weeks before tDCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Real tDCS + Placebo + Rehabilitation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Real tDCS, 2 mA for 20 mins per session, 10 sessions within 2 weeks&#xD;
Placebo oral intake daily for 3 months, since 2 weeks before tDCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tDCS + Placebo + Rehabilitation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham tDCS, ramped up over 10 seconds and then reduced to 0mA, 10 sessions within 2 weeks&#xD;
Placebo oral intake daily for 3 months, since 2 weeks before tDCS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tDCS</intervention_name>
    <description>dual tDCS with ipsilesional primary motor cortex (M1) anodal stimulation and contralesional M1 cathodal stimulation, 2 weeks after SSRI treatment</description>
    <arm_group_label>Real tDCS + Citalopram + Rehabilitation</arm_group_label>
    <arm_group_label>Real tDCS + Placebo + Rehabilitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <description>total 3 months, since 2-4 weeks after stroke</description>
    <arm_group_label>Real tDCS + Citalopram + Rehabilitation</arm_group_label>
    <arm_group_label>Sham tDCS + Citalopram + Rehabilitation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Rehabilitation</intervention_name>
    <description>hospitalized rehabilitation, 3 hours daily</description>
    <arm_group_label>Real tDCS + Citalopram + Rehabilitation</arm_group_label>
    <arm_group_label>Real tDCS + Placebo + Rehabilitation</arm_group_label>
    <arm_group_label>Sham tDCS + Citalopram + Rehabilitation</arm_group_label>
    <arm_group_label>Sham tDCS + Placebo + Rehabilitation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged 20-80;&#xD;
&#xD;
          -  first-onset stroke&#xD;
&#xD;
          -  brain image confirmed unilateral subcortical infarction&#xD;
&#xD;
          -  moderate to severe upper-limb impairment (SAFE score &lt;8).&#xD;
&#xD;
          -  3 days to 4 weeks after stroke onset&#xD;
&#xD;
          -  stable medical condition&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  metal implants, such as electrodes or pacemaker&#xD;
&#xD;
          -  epilepsy history or active spikes from EEG recording&#xD;
&#xD;
          -  major depression or taking psychoactive drugs&#xD;
&#xD;
          -  alcoholism or drug abuse history&#xD;
&#xD;
          -  combined with other severe neurological or psychiatric diagnoses&#xD;
&#xD;
          -  pregnancy or breastfeeding;&#xD;
&#xD;
          -  other contraindications to brain MRI, such as severe claustrophobia&#xD;
&#xD;
          -  intolerance to electrical stimulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Far Eastern Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Chih-Wei Tang</investigator_full_name>
    <investigator_title>Chief, Stroke Center</investigator_title>
  </responsible_party>
  <keyword>stroke, motor recovery, transcranial direct current stimulation, selective serotonin reuptake inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

